APA

Egeli U., Tezcan G., Cecener G., Tunca B., Demirdogen Sevinc E., Kaya E., Ak S., Dundar H. Z., Sarkut P., Ugras N., Yerci O., Ozen Y. & Evrensel T. (20180425). miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. : Pancreas.

Chicago

Egeli Unal, Tezcan Gulcin, Cecener Gulsah, Tunca Berrin, Demirdogen Sevinc Elif, Kaya Ekrem, Ak Secil, Dundar Halit Ziya, Sarkut Pinar, Ugras Nesrin, Yerci Omer, Ozen Yilmaz and Evrensel Turkkan. 20180425. miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. : Pancreas.

Harvard

Egeli U., Tezcan G., Cecener G., Tunca B., Demirdogen Sevinc E., Kaya E., Ak S., Dundar H. Z., Sarkut P., Ugras N., Yerci O., Ozen Y. and Evrensel T. (20180425). miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. : Pancreas.

MLA

Egeli Unal, Tezcan Gulcin, Cecener Gulsah, Tunca Berrin, Demirdogen Sevinc Elif, Kaya Ekrem, Ak Secil, Dundar Halit Ziya, Sarkut Pinar, Ugras Nesrin, Yerci Omer, Ozen Yilmaz and Evrensel Turkkan. miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. : Pancreas. 20180425.